ATLAS: Patient-Reported Outcomes From Phase III Study of Switch to Long-Acting Injectable Cabotegravir + Rilpivirine in Virologically Suppressed Patients

July 21-24, 2019; Mexico City, Mexico
97% of patients receiving long-acting injectable therapy said that they preferred it to continued daily oral ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 223 KB
Released: July 25, 2019

Acknowledgements

Provided by USF

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@health.usf.edu
http://www.cme.hsc.usf.edu

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Downloadable audio from Jürgen K. Rockstroh, MD, with analysis of key new HIV data from IAS 2019 on NTD risk in pregnancy, PrEP, and emerging ART options

Jürgen K. Rockstroh, MD Released: August 20, 2019

Jürgen K. Rockstroh, MD, on IAS 2019 data reporting phase III safety and efficacy of dual therapy with dolutegravir plus lamivudine (GEMINI and TANGO)

Jürgen K. Rockstroh, MD Released: August 20, 2019

CCO downloadable slides on new HIV data from IAS 2019: PrEP, first-line and switch options, NTD risk with ART at conception, and investigational drugs

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Paul E. Sax, MD
Released: August 15, 2019

Free downloadable slides on HIV treatment and prevention highlights from IAS 2019 chosen by expert faculty, reported by Clinical Care Options

Brenda E. Crabtree Ramírez, MD Anton L. Pozniak, MD, FRCP Released: August 2, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?